Standard Versus Extended Pancreaticoduodenectomy in Treating Adenocarcinoma of the Head of the Pancreas

doi:10.1016/S1001-9294(13)60031-0

Abstract

Between January 1994 and December 2011, 165 patients with biopsy-proven adenocarcinoma of the pancreatic head were treated in West China Hospital, among whom 93 underwent SPD and 72 had EPD. Complications and survival after the surgery were analyzed retrospectively.

The median operation time of the EPD group was longer compared with the SPD group (375 minutes vs.310 minutes, P<0.01), the volume of blood transfusion was larger (700 mL vs.400 mL, P<0.05), while the median hospital stay (13.5 days vs.12 days, P= 0.79) and the total complication rates were comparable (34.7% vs.32.4%, P=0.93). The total recurrence rates of the SPD and EPD groups were not significantly different (52.7% vs. 43.1%, P=0.83). No significant differences were found between the SPD and EPD groups in 1-year (81.7% vs. 86.1%), 3-year (38.7% vs. 43.1%), 5-year (16.7% vs. 19.4%), and median survivals (19.8 months vs. 23.2 months, P= 0.52).

The postoperative complications and survival donot differ significantly between SPD and EPD.

Key words: pancreas, cancer, pancreaticoduodenectomy, standard resection, extended resection

Jun Gong, Gang Mai, Zhen-jiang Zheng, Guang-ming Xiang, Wei-ming Hu, Bo-le Tian, Zhao-da Zhang, and Xu-bao Liu. Standard Versus Extended Pancreaticoduodenectomy in Treating Adenocarcinoma of the Head of the Pancreas[J].Chinese Medical Sciences Journal, 2013, 28(2): 107-112.

References 35

1.	Jemal A, Siegel R, Ward E,et al. Cancer statistics, 2006.
	CA Cancer J Clin 2006; 56:106-30.
2.	Ferlay J, Shin HR, Bray F,et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3.	O00092;Sullivan A, Kocher HM. Pancreatic cancer. Clin Evid (Online) 2007;2007:0409.
4.	Lillemoe KD, Grosfeld JL. Pancreatic cancer - progress made. J Am Coll Surg 2007;205:S87-9.
5.	Ueda M, Endo I, Nakashima M,et al. Prognostic factors after resection of pancreatic cancer. World J Surg 2009;33:104-10.
6.	Zacharias T, Jaeck D, Oussoultzoglou E,et al. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11:350-6.
7.	Bosman FT,Carneiro F,Hruban RH,et al Tumours of the pancreas. In:WHO Classification of Tumours of the Digestive Syste.Lyon:IARC Press;2010. p.219-50.
8.	Edge SB, Compton CC. The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
9.	Hackert T, B000fc;chler MW, Werner J. Current state of surgical management of pancreatic cancer. Cancer 2011;3:1253-73.
10	Mancuso A, Calabr000f2; F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006;58:213-41.
11	Linder S, Bostr000f6;m L, Nilsson B. Pancreatic cancer in Sweden 1980-2000:a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies. J Gastrointest Surg 2006;10:672-8.
12	Kuhlmann KF, de Castro SM, Wesseling JG,et al. Surgical treatment of pancreatic adenocarcinoma:actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549-58.
13	Ruiz-Tovar J, Mart000ed;n-P000e9;rez E, Fern000e1;ndez-Contreras ME,et al. Identification of prognostic factorsin pancreatic cancer. Cir Cir 2011;79:313-22.
14	Yeo CJ, Cameron JL, Sohn TA. et al, Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s:pathology, complications, and outcomes. Ann Surg 1997;226:248-57.
15	Simunovic M, To T, Theriault M,et alRelation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system,. CMAJ 1999; 160:643-8.
16	Reddy SK, Tyler DS, Pappas TN,et al. Extended resection for pancreatic adenocarcinoma. Oncologist 2007;12:654-63.
17	O00092;Morchoe CC. Lymphatic system of the pancreas. Microsc Res Tech 1997;37:456-77.
18	Sakai M, Nakao A, Kaneko T,et al. Para-aortic lymph node metastasis in carcinoma of the head of the pancreas. Surgery 2005;137:606-11.
19	Freelove R, Walling AD. Pancreatic cancer:diagnosis and management. Am Fam Physician 2006;73:485-92.
20	Salin TT, Fujii T, Kanda M,et al. Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas. Pancreas 2011;40:1029-33.
21	Yamamoto J, Saiura A, Koga R,et al. Improved survival of left-sided pancreas cancer after surgery. Jpn J Clin Oncol 2010;40:530-6.
22	Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol 1995;17:139-46.
23	Verbeke CS, Leitch D, Menon KV,et al. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-7.
24	Cecil TD, Sexton R, Moran BJ,et al. Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Dis Colon Rectum 2004;47:1145-9.
25	B000fc;chler P, Friess H, M000fc;ller M,et al. Survival benefit of extended resection in pancreatic cancer. Am J Surg 2007;194:S120-6.
26	Capussotti L, Massucco P, Ribero D,et al. Extended lymphadenectomy and vein resection for pancreatic head cancer:outcomes and implications for therapy. Arch Surg 2003;138:1316-22.
27	Yeo CJ, Cameron JL, Lillemoe KD,et al. Pancreaticoduo- denectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adeno- carcinoma, part 2:randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355-66.
28	Michalski CW, Kleeff J, Wente MN,et al. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pan- creatic cancer. Br J Surg 2007;94:265-73.
29	Iacono C, Accordini S, Bortolasi L,et al. Results of pancreaticoduodenectomy for pancreatic cancer:exten- ded versus standard procedure. World J Surg 2002;26:1309-14.
30	Yang YM, Wan YL, Tian XD,et al. Outcome of pancreatico- duodenectomy with extended retroperitoneal lympha- denectomy for adenocarcinoma of the head of the pancreas. Chin Med J (Engl) 2005;118:1863-9.
31	Popiela T, Kedra B, Sierzega M. Does extended lympha- denectomy improve survival of pancreatic cancer patients? Acta Chir Belg 2002;102:78-82.
32	Lin CC, Chen CL, Cheng YF. Modified extended distal pancreatectomy for carcinoma of body and tail of pancreas. Hepatogastroenterology 2005;52:1090-1.
33	Farnell MB, Pearson RK, Sarr MG,et al. A prospective randomized trial comparing standard pancreatoduodenec- tomy with pancreatoduodenectomy with extended lymph- adenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-28.
34	Riediger H, Keck T, Wellner U,et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.
35	Pedrazzoli S, DiCarlo V, Dionigi R,et al. Standard versus extended lymphadenectomy associated with pancrea- ticoduodenectomy in the surgical treatment of adeno- carcinoma of the head of the pancreas:a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-17.

[1]	Siwen Ouyang, Weiming Kang. Research Advances in the Role of Keratins in Gastrointestinal Cancer [J]. Chinese Medical Sciences Journal, 2022, 37(1): 73-78.
[2]	Liang Wang, Gang Li, Yun-tao Bing, Mao-lin Tian, Hangyan Wang, Chunhui Yuan, Dianrong Xiu. Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors? [J]. Chinese Medical Sciences Journal, 2021, 36(4): 284-294.
[3]	Wei Yang, Mei Zhang. Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments [J]. Chinese Medical Sciences Journal, 2021, 36(4): 333-341.
[4]	Chen Xu, Huo Xiaofei, Wu Zhe, Lu Jingjing. Advances of Artificial Intelligence Application in Medical Imaging of Ovarian Cancers [J]. Chinese Medical Sciences Journal, 2021, 36(3): 196-203.
[5]	Xu Chen, Hongling Liu, Fenghui Zhao, Zongxian Jiao, Jinsui Wang, Yamei Dang. Wnt5a Plays Controversial Roles in Cancer Progression [J]. Chinese Medical Sciences Journal, 2020, 35(4): 357-365.
[6]	Xiaoqi Zeng, Shanshan Jiang, Yuanyang Peng, Minfeng Liu, Changsheng Ye, Jianyu Dong. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review [J]. Chinese Medical Sciences Journal, 2020, 35(4): 377-382.
[7]	Li Wenxing, Zhang Yanli. Novel Long Non-coding RNA Markers for Prognostic Prediction of Patients with Bladder Cancer [J]. Chinese Medical Sciences Journal, 2020, 35(3): 239-247.
[8]	Wang Zhan, Wang Xu, Wang Wenda, Zheng Guoyang, Guo Hao, Zhang Yushi. Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Predicting Prognosis of Surgically Resectable Urinary Cancers: Systematic Review and Meta-Analysis [J]. Chinese Medical Sciences Journal, 2020, 35(3): 262-271.
[9]	Xu Longming,Dai Shuiping,Zuo Yunxia. Impacts of Preoperative Smoking and Smoking Cessation Time on Preoperative Peripheral Blood Inflammatory Indexes and Postoperative Hospitalization Outcome in Male Patients with Lung Cancer and Surgery Treatment [J]. Chinese Medical Sciences Journal, 2020, 35(2): 170-178.
[10]	Zhang Ling, Sun Lei, Mu Xiaoyan, Ji Youxin. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer [J]. Chinese Medical Sciences Journal, 2019, 34(4): 292-296.
[11]	Liang Xi, Hu Jingnan, He Jianming. An Optimized Protocol of Azoxymethane-Dextran Sodium Sulfate Induced Colorectal Tumor Model in Mice [J]. Chinese Medical Sciences Journal, 2019, 34(4): 281-288.
[12]	Bao Yi, Mo Juanfen, Wu Jiayuan, Cao Chenxi. Expression of PD1 and BTLA on the CD8⁺ T Cell and γδT Cell Subsets in Peripheral Blood of Non-Small Cell Lung Cancer Patients [J]. Chinese Medical Sciences Journal, 2019, 34(4): 248-255.
[13]	Wang Guorong, Wang Zhiwei, Jin Zhengyu. Application and Progress of Texture Analysis in the Therapeutic Effect Prediction and Prognosis of Neoadjuvant Chemoradiotherapy for Colorectal Cancer [J]. Chinese Medical Sciences Journal, 2019, 34(1): 45-50.
[14]	Liu Qian, Ning Xiaohong, Wang Lei, Liu Wei. Individualized Aromatherapy in End-of-Life Cancer Patients Care: A Case Report [J]. Chinese Medical Sciences Journal, 2018, 33(4): 234-239.
[15]	Zhu Yi. Value-based Practice: Integration of Cancer Rehabilitation and Palliative Care in Oncology Services [J]. Chinese Medical Sciences Journal, 2018, 33(4): 204-209.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center